Form 4: Metsera Director Berns Reports Share Disposition Post-Pfizer Merger

Paul L. Berns, a director of Metsera, Inc., reported the disposition of all his direct and indirect beneficial ownership in Metsera common stock, restricted stock units, and stock options following the company's merger with Pfizer Inc. on November 13, 2025.

Summary

• Metsera, Inc. merged with Pfizer Inc.'s wholly-owned subsidiary, Mayfair Merger Sub, Inc., on November 13, 2025, resulting in Metsera becoming a wholly-owned subsidiary of Pfizer Inc.
• Each outstanding share of Metsera common stock was automatically converted into the right to receive $65.60 in cash per share and one contractual contingent value right (CVR).
• Paul L. Berns, a director, disposed of 4,031 directly held common shares, 7,523,682 indirectly held common shares, 8,313,680 indirectly held common shares, and 957,559 directly held common shares, resulting in 0 shares beneficially owned post-transaction.
• Berns' 4,031 Restricted Stock Units (RSUs) were cancelled and converted into a cash amount equal to $65.60 multiplied by the number of shares underlying the RSU, plus a corresponding number of CVRs, with no vesting applicable to these payments.
• Berns' stock options (24,188 options with an exercise price of $29.25 and 223,430 options with an exercise price of $8.18) were cancelled in exchange for cash payments (calculated as the Closing Amount minus the exercise price, multiplied by the number of shares subject to the option) and CVRs.
• For unvested stock options, the cash payment and CVRs are subject to the original vesting schedule, with full vesting upon the first anniversary of the merger, contingent on the holder's continued service with Pfizer or its subsidiaries.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The merger provides a clear exit for shareholders with a significant cash component and potential upside from CVRs. However, the loss of independence and the contingent nature of CVRs introduce some uncertainty. For the reporting person, it represents a conversion of equity and options into cash and CVRs, marking a successful liquidity event.

Positives

• Metsera shareholders received a fixed cash payment of $65.60 per share, providing immediate liquidity and a defined return.
• Shareholders also received Contingent Value Rights (CVRs), offering potential additional payments upon the achievement of specified milestones.
• Restricted Stock Units (RSUs) held by the reporting person were converted to cash and CVRs with no further vesting requirements, providing immediate value.
• The merger indicates a successful acquisition for Metsera, potentially validating its technology or market position.

Negatives

• Metsera, Inc. ceased to be an independent publicly traded entity, meaning its common stock is no longer traded.
• Stock option holders with unvested options will have their cash payments and CVRs subject to a continued service requirement with Pfizer for one year post-merger.
• The value of Contingent Value Rights (CVRs) is contingent and uncertain, dependent on future milestone achievements.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and depends on the achievement of specific milestones, which may or may not occur.
• Unvested stock option holders face the risk of forfeiture of their contingent cash and CVR payments if they do not maintain continued service with Pfizer or its subsidiaries through the first anniversary of the merger.
• Shareholders no longer participate in the future growth or decline of Metsera as an independent entity.

Future Outlook

The merger with Pfizer Inc. means Metsera, Inc. will operate as a wholly-owned subsidiary, with its former shareholders receiving a fixed cash amount and contingent value rights tied to future milestone achievements. The future financial performance of Metsera will be integrated into Pfizer's reporting, and the value of the CVRs will depend on the achievement of specified milestones.

Management Comments

• Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025, by and among Metsera, Inc., Pfizer Inc., and Mayfair Merger Sub, Inc., the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent.
• At the Effective Time of the Merger, each issued and outstanding share of common stock... was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest... plus (ii) one contractual contingent value right representing the right to receive contingent payments... upon the achievement of certain specified milestones.
• Each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option... and (y) one CVR for each share of the Common Stock subject to such stock option.
• In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options, except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger.
• Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU... and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. There is no vesting applicable to the cash payment and the CVRs.

Industry Context

This acquisition by Pfizer Inc. of Metsera, Inc. reflects a common trend in the pharmaceutical and biotechnology sectors where larger established companies acquire smaller, innovative firms to bolster their pipelines, gain access to new technologies, or expand into new therapeutic areas. The use of Contingent Value Rights (CVRs) is also a frequent mechanism in such deals, allowing the acquirer to mitigate risk by tying a portion of the acquisition cost to the successful achievement of future development or commercial milestones, while providing target shareholders with potential upside beyond the upfront cash payment.

Comparison to Industry Standards

• The use of a fixed cash payment combined with Contingent Value Rights (CVRs) is a standard acquisition structure in the biotech and pharmaceutical industry, similar to deals like Sanofi's acquisition of Kadmon Holdings or Bristol Myers Squibb's acquisition of MyoKardia, where CVRs were used to bridge valuation gaps and share future risks/rewards.
• The $65.60 per share cash consideration would need to be compared to Metsera's pre-merger trading price and analyst price targets to assess its premium relative to industry averages for similar-stage biotech acquisitions.
• The vesting conditions for unvested stock options, requiring continued service for one year post-merger, are typical for retaining key personnel during integration phases in M&A transactions across various industries.

Related Party Transactions

• Paul L. Berns, as a member of the investment committee of AVP XIII LLC, may be deemed to share the power to direct the disposition and vote of shares held by ARCH Venture Fund XIII, L.P., which indirectly held a significant number of Metsera common shares.

Stakeholder Impact

• Shareholders: Received $65.60 cash per share and one CVR, providing immediate liquidity and potential future payments, but losing direct equity in Metsera.
• Employees (especially those with unvested options): Those with unvested stock options are incentivized to continue service with Pfizer for one year post-merger to fully vest their cash and CVR payments.
• Metsera Management/Board: The company is now a wholly-owned subsidiary, implying changes in operational autonomy and reporting structure.
• Pfizer Inc.: Gains Metsera's assets, pipeline, and intellectual property, potentially strengthening its market position or therapeutic offerings.

Next Steps

• Pfizer Inc. will integrate Metsera, Inc. as a wholly-owned subsidiary.
• The contingent value rights (CVRs) will be managed by Equiniti Trust Company, LLC, with payments contingent upon the achievement of specified milestones.
• Unvested stock option holders must continue service with Pfizer or its subsidiaries for one year post-merger to receive their full cash and CVR payments.

Key Dates

Keywords

Metsera, Pfizer, Merger, Acquisition, Form 4, Beneficial Ownership, Stock Options, RSUs, Contingent Value Rights, CVR, Paul L. Berns, MTSR